S
Sandy Elbitar
Researcher at Saint Joseph's University
Publications - 12
Citations - 228
Sandy Elbitar is an academic researcher from Saint Joseph's University. The author has contributed to research in topics: PCSK9 & Familial hypercholesterolemia. The author has an hindex of 6, co-authored 9 publications receiving 182 citations. Previous affiliations of Sandy Elbitar include French Institute of Health and Medical Research & Saint Joseph University.
Papers
More filters
Journal ArticleDOI
Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.
Marianne Abifadel,Sandy Elbitar,Petra El Khoury,Petra El Khoury,Youmna Ghaleb,Melody Chemaly,Marie-Line Moussalli,Jean-Pierre Rabès,Mathilde Varret,Mathilde Varret,Catherine Boileau,Catherine Boileau +11 more
TL;DR: The promising results in lowering LDL cholesterol levels raise hope that the PCSK9 adventure will lead, after the large and long-term ongoing phase III studies evaluating efficacy and safety, to a new anticholesterol pharmacological class.
Journal ArticleDOI
PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies.
Petra El Khoury,Petra El Khoury,Sandy Elbitar,Sandy Elbitar,Youmna Ghaleb,Youmna Ghaleb,Yara Abou Khalil,Yara Abou Khalil,Mathilde Varret,Mathilde Varret,Catherine Boileau,Catherine Boileau,Marianne Abifadel,Marianne Abifadel +13 more
TL;DR: The evolution of research on PCSK9, starting from the discovery of the first set of mutations in PCSK7 in FH in 2003 to the latest clinical trials with the anti-PCSK9 antibodies, shows how rigorous and powered genetic analyses can lead to a new class of lipid-lowering drugs that give hope in fighting high cholesterol levels and their cardiovascular complications.
Journal ArticleDOI
New Sequencing technologies help revealing unexpected mutations in Autosomal Dominant Hypercholesterolemia.
Sandy Elbitar,Sandy Elbitar,Sandy Elbitar,Delia Susan-Resiga,Youmna Ghaleb,Youmna Ghaleb,Youmna Ghaleb,Petra El Khoury,Petra El Khoury,Gina M. Peloso,Nathan O. Stitziel,Jean-Pierre Rabès,Jean-Pierre Rabès,Valérie Carreau,Josée Hamelin,Ali Ben-Djoudi-Ouadda,Eric Bruckert,Catherine Boileau,Catherine Boileau,Nabil G. Seidah,Mathilde Varret,Mathilde Varret,Marianne Abifadel,Marianne Abifadel +23 more
TL;DR: This work shows that Next-Generation Sequencing (exome, genome or targeted sequencing) are powerful tools to find new mutations and identify compound heterozygotes, which will lead to better diagnosis and treatment of ADH.
Journal ArticleDOI
Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015).
Sandy Elbitar,Petra El Khoury,Youmna Ghaleb,Jean-Pierre Rabès,Mathilde Varret,Nabil G. Seidah,Catherine Boileau,Marianne Abifadel +7 more
TL;DR: The different strategies that are pursued to modulate the functional activity of PCSK9 for lowering LDL-cholesterol levels are reviewed, focusing on anti-PCSK9 monoclonal antibodies and the related clinical trials.
Journal ArticleDOI
Usefulness of the genetic risk score to identify phenocopies in families with familial hypercholesterolemia
Youmna Ghaleb,Youmna Ghaleb,Youmna Ghaleb,Sandy Elbitar,Sandy Elbitar,Sandy Elbitar,Petra El Khoury,Petra El Khoury,Eric Bruckert,Valérie Carreau,Alain Carrié,Philippe Moulin,M. Di-Filippo,Sybil Charrière,Harout Iliozer,Michel Farnier,Gérald Luc,Jean-Pierre Rabès,Catherine Boileau,Catherine Boileau,Marianne Abifadel,Marianne Abifadel,Mathilde Varret,Mathilde Varret +23 more
TL;DR: The GRS can be used as a marker of the severity of hypercholesterolemia but does not seem to be a reliable tool to distinguish phenocopies within FH families.